2014 Fiscal Year Final Research Report
Design and Evaluation of Next Generation Albumin-thioredoxin Fusion Protein for Multiple Organ Failure Treatment
| Project/Area Number |
24390043
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MARUYAMA Toru 熊本大学, 薬学部, 教授 (90423657)
WATANABE Hiroshi 熊本大学, 薬学部, 准教授 (70398220)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | アルブミン / ナノメディスン / レドックス / 多臓器不全治療 / 病態モデル / 肺障害 / 肝障害 / 腎障害 |
|---|
| Outline of Final Research Achievements |
This research investigated the therapeutic effect of albumin-thioredoxin (HSA-Trx) on multiple organ failure model using mouse models of primary organ failure such as lungs, liver and kidney.
1) HSA-Trx was found to produce effective therapeutic effect in Bleomycin induced pulmonary fibrosis. 2) The inhibitory effect of fusion protein on acetaminophen induced liver disorder was found to occur in a concentration dependent manner. 3) Effectiveness of the fusion protein in cisplatin nephropathy was evaluated. The fusion protein was found to inhibit increases in SCr, BUN and NAG activity, as well as reduction in CLcr.
|
| Free Research Field |
薬物動態学、DDS
|
